已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

A Drug–Drug Interaction Study of a Novel Selective Urate Reabsorption Inhibitor, SHR4640, and Xanthine Oxidase Inhibitor, Febuxostat, in Patients With Primary Hyperuricemia

非布索坦 黄嘌呤氧化酶抑制剂 高尿酸血症 药理学 黄嘌呤氧化酶 最大值 药代动力学 尿酸 化学 医学 内科学 生物化学
作者
Chenjing Wang,Qing Yu,Xin Jiang,Yujie Deng,Feifei Sun,Xin Li,Ye Tao,Pingping Lin,Yaping Ma,Yuxian Zhu,Chengqian Li,Yu Cao
出处
期刊:The Journal of Clinical Pharmacology [Wiley]
卷期号:63 (2): 239-249 被引量:6
标识
DOI:10.1002/jcph.2159
摘要

Abstract SHR4640 is a novel, selective urate reabsorption inhibitor. As the mode of action of SHR4640 differs from that of a xanthine oxidase inhibitor, such as febuxostat, coadministration of these drugs may be a treatment option for patients with primary hyperuricemia. We assessed the potential drug–drug interaction between SHR4640 and febuxostat. In this single‐center, open‐label, randomized, drug–drug interaction study, subjects received 80 mg febuxostat or 10 mg SHR4640 alone daily in the first week, whereas during the second week a combination of SHR4640 and febuxostat was administered daily to all subjects. Plasma concentrations of SHR4640 and febuxostat were analyzed. We compared their pharmacokinetic and pharmacodynamic parameters and assessed both safety and tolerability. Compared with febuxostat alone, the geometric mean ratios (90%CIs) of the maximum concentration (C max ) and the area under the plasma concentration–time curve over the dosing interval τ (AUC 0–τ ) for febuxostat after coadministration were 1.284 (1.016 to 1.621) and 0.984 (0.876 to 1.106), respectively. The geometric mean ratios (90%CIs) of C max and AUC 0–τ for SHR4640 after coadministration compared with SHR4640 alone were 0.910 (0.839 to 0.988) and 0.929 (0.893 to 0.966), respectively. Febuxostat had no effect on SHR4640 pharmacokinetic parameters, as the 90%CIs of the geometric mean ratios were all within the range of 0.80 to 1.25. The coadministration of febuxostat and SHR4640 was well tolerated. The coadministration of SHR4640 with febuxostat was not associated with any clinically relevant pharmacokinetic drug interactions. SHR4640 combined with febuxostat had a synergistic effect on reducing uric acid in the pharmacodynamics, with the AUC decreasing from 7440 to 3170 h μmol/L compared with febuxostat alone and from 5730 to 2960 h μmol/L compared with SHR4640 alone.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
tomato709完成签到,获得积分10
2秒前
3秒前
时尚的未来完成签到 ,获得积分10
4秒前
huangxuliang发布了新的文献求助10
9秒前
kafm完成签到,获得积分10
9秒前
Hello应助xwwx采纳,获得10
10秒前
Good完成签到 ,获得积分10
13秒前
英姑应助iligll采纳,获得10
15秒前
20秒前
21秒前
紧张的钥匙完成签到 ,获得积分10
22秒前
爱笑的鹿完成签到,获得积分10
23秒前
小蘑菇应助俭朴的皮卡丘采纳,获得10
25秒前
26秒前
暴躁的凌柏完成签到 ,获得积分10
26秒前
30秒前
31秒前
xwwx发布了新的文献求助10
31秒前
32秒前
矜天完成签到 ,获得积分10
32秒前
丘比特应助超级小飞侠采纳,获得10
33秒前
kita完成签到 ,获得积分10
34秒前
zkx发布了新的文献求助10
36秒前
核桃应助逸风望采纳,获得20
36秒前
37秒前
女爰舍予完成签到 ,获得积分10
37秒前
zhoushishan完成签到,获得积分10
38秒前
过眼云烟完成签到,获得积分10
43秒前
李爱国应助shark采纳,获得10
46秒前
46秒前
美好善斓完成签到 ,获得积分10
48秒前
温暖砖头发布了新的文献求助10
49秒前
49秒前
库丽啦完成签到 ,获得积分10
50秒前
栗子应助科研通管家采纳,获得10
51秒前
51秒前
51秒前
ding应助科研通管家采纳,获得10
51秒前
GingerF应助科研通管家采纳,获得10
51秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
The Graphene Handbook (2019 Edition) 800
IEST-RP-CC018: Cleanroom Cleaning and Sanitization: Operating and Monitoring Procedures 600
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 600
久松真一著作集〈第5巻〉禅と芸術 500
Fundamentals of Modern Mathematics: A Practical Review (Dover Books on Mathematics) 500
Cold War Transcended: Australia's China Policy, 1949-1990 470
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6588261
求助须知:如何正确求助?哪些是违规求助? 8361271
关于积分的说明 17903934
捐赠科研通 5732452
什么是DOI,文献DOI怎么找? 2950494
邀请新用户注册赠送积分活动 1925869
关于科研通互助平台的介绍 1814062